Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Authors:
Open Access
- 1 March 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 178 (3) , 283-293
Abstract
Importance: Many pediatric patients with heterozygous familial hypercholesterolemia (HeFH) cannot reach recommended low-density lipoprotein cholesterol (LDL-C) concentrations on statins alone and require adjunct lipid-lowering therapy (LLT); the use of alirocumab in pediatric patients requires evaluation.Objective: To assess the efficacy of alirocumab in pediatric patients with inadequately controlled HeFH.Design, Setting, and Participants: This was a phase 3, randomized clinical trial conducted between May 2018 and August 2022 at 43 centers in 24 countries. Pediatric patients aged 8 to 17 years with HeFH, LDL-C 130 mg/dL or greater, and receiving statins or other LLTs were included. Following consecutive enrollment into dosing cohorts, 25 of 99 patients screened for dosing every 2 weeks (Q2W) failed screening; 25 of 104 patients screened for dosing every 4 weeks (Q4W) failed screening. A total of 70 of 74 Q2W patients (95%) and 75 of 79 Q4W patients (95%) completed the double-blind period.Interventions: Patients were randomized 2:1 to subcutaneous alirocumab or placebo and Q2W or Q4W. Dosage was based on weight (40 mg for Q2W or 150 mg for Q4W if P < .001) Q2W and −33.8% (97.5% CI, −46.4 to −21.2; P < .001) Q4W. Hierarchical analysis of secondary efficacy end points demonstrated significant improvements in other lipid parameters at weeks 12 and 24 with alirocumab. Two patients receiving alirocumab Q4W experienced adverse events leading to discontinuation. No significant difference in adverse event incidence was observed between treatment groups. Open-label period findings were consistent with the double-blind period.Conclusions and Relevance: The findings in this study indicate that alirocumab Q2W or Q4W significantly may be useful for reducing LDL-C and other lipid parameters and be well tolerated in pediatric patients with HeFH inadequately controlled with statins.Trial Registration: ClinicalTrials.gov Identifier: NCT03510884Keywords
This publication has 28 references indexed in Scilit:
- Clinical Genetic Testing for Familial HypercholesterolemiaJACC, 2018
- Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in NorwayJournal of Clinical Lipidology, 2018
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or HigherCardiovascular Drugs and Therapy, 2016
- Cardiovascular risk stratification in familial hypercholesterolaemiaHeart, 2016
- ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaEuropean Heart Journal, 2015
- Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatmentEuropean Heart Journal, 2015
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialThe Lancet, 2015
- Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising their Suitability in the Omani Arab PopulationOman Medical Journal, 2014
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary ReportPediatrics, 2011